Biopharma firm Adlai Nortye opens new U.S. HQ in N.J.

Adlai Nortye Ltd., a biopharmaceutical company, has opened its new U.S. headquarters in North Brunswick, it announced Tuesday.

The announcement was held during a ceremony at the Biotechnology Development Center. The new headquarter location marks the company’s global expansion and follows the recent launch of its first international translational medicine laboratory in Boston.

Attending the ceremony were Carsten Lu, Adlai Nortye CEO; Dr. Lars Birgerson, CEO, president and chief development officer; Assemblyman Andrew Zwicker; Tim Sullivan, New Jersey Economic Development Authority CEO; Dr. Prabhas Moghe, vice chancellor for research and innovation, Rutgers University; and Jijun Xing, science and technology counselor, consulate general of the People’s Republic of China in New York.

“We are a leading R&D driven pharmaceutical company with a growing staff and a uniquely rich pipeline of late-stage treatments. Today, with the opening of our new U.S. headquarters, Adlai Nortye has taken another major step in our goal to become an international player. We are ready to make greater breakthroughs in the field of immuno-oncology, to make more drugs be successfully approved and marketed,” Lu said.

“Where better to build a US HQ than New Jersey, the heart of the American pharmaceutical industry. The location is especially perfect as it will also provide us with an opportunity to combine our US HQ and development center with our antibody research group here in the science park,” said Bigerson.